Visioneering Technologies Inc. has requested an immediate suspension from ASX trading as it prepares for removal from the official list, raising questions about the company’s future.
Visioneering Technologies reported a mixed Q4 FY'24 with a slight revenue decline but stronger cash flow and expanding global footprint, underpinned by promising clinical trial data.
Visioneering Technologies reports promising interim results from its PROTECT trial, showing significant control of myopia progression in children using NaturalVue® Multifocal lenses.